{"product_id":"anti-human-cd20-monoclonal-antibody-ofatumumab-ua016165","title":"Anti-Human CD20 Monoclonal Antibody (Ofatumumab)","description":"\u003ch4\u003eProduct Specification\u003c\/h4\u003e\u003cdiv class=\"responsive-table product-detail-table details-table\"\u003e\n\u003cbr\u003e\u003ctable style=\"width: 100%; height: auto;\"\u003e\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eHost\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHuman\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eSynonyms\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eOfatumumab\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eConcentration\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e2mg\/mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eExpression System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eHEK293\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eConjugation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eUnconjugated\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003ePhysical Appearance\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003eLiquid\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eStorage Buffer\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003ePBS pH7.4, containing no preservative\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eStability \u0026amp; Storage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\n\u003cp\u003e\u003cspan\u003e2 to 8 °C for 2 weeks under sterile conditions;\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e-20 °C for 3 months under sterile conditions; \u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003e-80 °C for 24 months under sterile conditions.\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan\u003ePlease avoid repeated freeze-thaw cycles.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 22%;\"\u003e\u003cstrong\u003eReference\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"width: 78%;\"\u003e\u003cp\u003e1. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020 Aug 6;383(6):546-557.\u003cbr\u003e2. Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, Kappos L. Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Mult Scler. 2022 Sep;28(10):1562-1575.\u003c\/p\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\u003c\/table\u003e\n\u003c\/div\u003e\u003ch4\u003eBackground\u003c\/h4\u003e\u003cdiv\u003e\u003cp\u003e\u003cspan\u003eOfatumumab is a fully humanized monoclonal antibody that targets the CD20 molecule on the surface of B cells. Its core mechanism of action involves binding to the CD20 protein, thereby triggering multiple effector functions—including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis—to efficiently deplete CD20-positive B lymphocytes. Clinically, ofatumumab has a dual application: the intravenous formulation (Arzerra®) is indicated for the treatment of chronic lymphocytic leukemia, while the subcutaneous formulation (Kesimpta®) has been approved for the management of adult relapsing forms of multiple sclerosis, effectively reducing relapse rates and delaying disability progression. Notably, its convenient once\u003c\/span\u003e\u003cspan\u003e‑\u003c\/span\u003e\u003cspan\u003emonthly, at\u003c\/span\u003e\u003cspan\u003e‑\u003c\/span\u003e\u003cspan\u003ehome self\u003c\/span\u003e\u003cspan\u003e‑\u003c\/span\u003e\u003cspan\u003eadministration regimen offers significant advantages in facilitating long\u003c\/span\u003e\u003cspan\u003e‑\u003c\/span\u003e\u003cspan\u003eterm disease management for patients with multiple sclerosis.\u003c\/span\u003e\u003c\/p\u003e\u003c\/div\u003e","brand":"UA BIOSCIENCE","offers":[{"title":"25μL","offer_id":42887927234635,"sku":"UA016165-25μL","price":90.0,"currency_code":"USD","in_stock":true},{"title":"100μL","offer_id":42887927267403,"sku":"UA016165-100μL","price":185.0,"currency_code":"USD","in_stock":true},{"title":"500μL","offer_id":42887927300171,"sku":"UA016165-500μL","price":455.0,"currency_code":"USD","in_stock":true},{"title":"1mL","offer_id":42887927332939,"sku":"UA016165-1mL","price":685.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0590\/8375\/1499\/files\/AntBioImage_a6ac524a-ebd1-4ea7-a423-6b23d09fe6b4.png?v=1783774839","url":"https:\/\/www.antbioinc.com\/products\/anti-human-cd20-monoclonal-antibody-ofatumumab-ua016165","provider":"AntBio","version":"1.0","type":"link"}